

RECEIVED

1647

JUL 31 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO BOX 1450, Alexandria, Virginia 22313-1450, on JULY 24, 2003 RECH CENTER 16302000



C. FONG

PATENT

Attorney Docket No. 39780-2630P1C4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application)	<u>PATENT APPLICATION</u>	#14
)		M.J.
Inventor(s): Avi Ashkenazi et al.)	Art Unit: 1647	
)		
Application No.: 09/978,191)	Examiner: To Be Assigned	
)		
Filed: October 15, 2001)		
)		
Title Secreted and Transmembrane Polypeptides and Nucleic Acids Encoding The Same)		
)		
)		

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- (2) It is being filed within 3 months of entry of a national stage
-- OR --
- (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- a certification as specified in §1.97(e) is provided below; or
- a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39780-2630P1C4).


Respectfully submitted,

HELLER EHRLMAN WHITE & MCAULIFFE LLP

Dated: July 28, 2003

By: 
Anna L. Barry; Reg. No. 51,436

275 Middlefield Road
Menlo Park, CA 94025-3506
(650) 324-7000
Customer No. 35489

INFORMATION DISCLOSURE STATEMENT PTO-1449 		ATTY. DOCKET NO. 39780-2630P1C4		SERIAL NO. 09/978,191			
		APPLICANT Ashkenazi et al.					
				FILING DATE 10/15/01			
						GROUP: 1647	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 98/57983	12/23/98	PCT	C07K	14/00	<input type="checkbox"/>	<input type="checkbox"/>
	WO 99/54353	10/28/99	PCT	C07K	14/47	<input type="checkbox"/>	<input type="checkbox"/>
	WO 99/54437	10/28/99	PCT	C12N		<input type="checkbox"/>	<input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Hillier, L. et al., "WashU-Merck EST Project 1997", Accession No.: AA448958, ss.DNA30943, est. 10 Jun 1997, unpublished						
	Hillier, L. et al., "WashU-Merck EST Project 1997", Accession No.: AA448958, ss.DNA64907, est. 10 Jun 1997, unpublished						
	Hillier, L. et al., "WashU-Merck EST Project 1997", Accession No.: AA448958, ss.DNA64908, est. 10 Jun 1997, unpublished						
	Hillier, L. et al., "The WashU-Merck EST Project", Accession No.: N70081, ss.DNA30943, est. 16 Mar 1996, unpublished.						
	Hillier, L. et al., "The WashU-Merck EST Project", Accession No.: N70081, ss.DNA64907, est. 16 Mar 1996, unpublished.						
	Hillier, L. et al., "The WashU-Merck EST Project", Accession No.: N70081, ss.DNA64908, est. 16 Mar 1996, unpublished.						
	Specht, T. et al., "The Nucleic Acid Sequences Expressed in Normal Uterine Tissues, and Derived Polypeptides, For Treatment of Uterine Cancer and Identification of Therapeutic Agents", Dayhoff Accession No.: P_AAY59870, p1.DNA30943, DE-19817946-A1, filed: 17 April 1999, pub 21 Oct 1999.						
	Specht, T. et al., "The Nucleic Acid Sequences Expressed in Normal Uterine Tissues, and Derived Polypeptides, For Treatment of Uterine Cancer and Identification of Therapeutic Agents", Dayhoff Accession No.: P_AAY59870, p1DNA64907, , DE-19817946-A1, filed: 17 April 1999, pub 21 Oct 1999.						
	Specht, T. et al., "The Nucleic Acid Sequences Expressed in Normal Uterine Tissues, and Derived Polypeptides, For Treatment of Uterine Cancer and Identification of Therapeutic Agents", Dayhoff Accession No.: P_AAY59870, p1.DNA64908, , DE-19817946-A1, filed: 17 April 1999, pub 21 Oct 1999.						
EXAMINER		DATE CONSIDERED					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 39780-2630P1C4	SERIAL NO. 09/978,191				
PTO-1449		APPLICANT Ashkenazi et al.	JUL 31 2003 RECEIVED U.S. PATENT AND TRADEMARK OFFICE TECH CENTER 1600/2930				
		FILING DATE 10/15/01	GROUP: 1647				
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Specht, T. et al., "Human Nucleic Acid Sequences of Normal Uterus Tissue", GenBank Accession No.: ss.AX014304, ssDNA30943 WO 99/54353 filed 15 April 1999, pub. 28 Oct 1999.						
	Specht, T. et al., "Human Nucleic Acid Sequences of Normal Uterus Tissue", GenBank Accession No.: ss.AX014304, ssDNA64907, WO 99/54353 filed 15 April 1999, pub. 28 Oct 1999.						
	Specht, T. et al., "Human Nucleic Acid Sequences of Normal Uterus Tissue", GenBank Accession No.: ss.AX014304, ssDNA64908, WO 99/54353 filed 15 April 1999, pub. 28 Oct 1999.						
EXAMINER	DATE CONSIDERED						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.